These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

521 related articles for article (PubMed ID: 29214290)

  • 41. Retrospective study of advanced melanoma patients treated with ipilimumab after nivolumab: Analysis of 60 Japanese patients.
    Fujisawa Y; Yoshino K; Otsuka A; Funakoshi T; Uchi H; Fujimura T; Matsushita S; Hata H; Okuhira H; Tanaka R; Nagai K; Ishida Y; Nakamura Y; Furudate S; Yamamura K; Imafuku K; Yamamoto Y
    J Dermatol Sci; 2018 Jan; 89(1):60-66. PubMed ID: 29079332
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma.
    Weber JS; Kudchadkar RR; Yu B; Gallenstein D; Horak CE; Inzunza HD; Zhao X; Martinez AJ; Wang W; Gibney G; Kroeger J; Eysmans C; Sarnaik AA; Chen YA
    J Clin Oncol; 2013 Dec; 31(34):4311-8. PubMed ID: 24145345
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial.
    Weber JS; Gibney G; Sullivan RJ; Sosman JA; Slingluff CL; Lawrence DP; Logan TF; Schuchter LM; Nair S; Fecher L; Buchbinder EI; Berghorn E; Ruisi M; Kong G; Jiang J; Horak C; Hodi FS
    Lancet Oncol; 2016 Jul; 17(7):943-955. PubMed ID: 27269740
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma.
    Jansen YJL; Rozeman EA; Mason R; Goldinger SM; Geukes Foppen MH; Hoejberg L; Schmidt H; van Thienen JV; Haanen JBAG; Tiainen L; Svane IM; Mäkelä S; Seremet T; Arance A; Dummer R; Bastholt L; Nyakas M; Straume O; Menzies AM; Long GV; Atkinson V; Blank CU; Neyns B
    Ann Oncol; 2019 Jul; 30(7):1154-1161. PubMed ID: 30923820
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center.
    Horvat TZ; Adel NG; Dang TO; Momtaz P; Postow MA; Callahan MK; Carvajal RD; Dickson MA; D'Angelo SP; Woo KM; Panageas KS; Wolchok JD; Chapman PB
    J Clin Oncol; 2015 Oct; 33(28):3193-8. PubMed ID: 26282644
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Retrospective analysis of treatment-naive Slovenian patients with metastatic melanoma treated with pembrolizumab - real-world experience.
    Hribernik N; Boc M; Ocvirk J; Knez-Arbeiter J; Mesti T; Ignjatovic M; Rebersek M
    Radiol Oncol; 2020 Jan; 54(1):119-127. PubMed ID: 31955148
    [TBL] [Abstract][Full Text] [Related]  

  • 47. MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial.
    Dreno B; Thompson JF; Smithers BM; Santinami M; Jouary T; Gutzmer R; Levchenko E; Rutkowski P; Grob JJ; Korovin S; Drucis K; Grange F; Machet L; Hersey P; Krajsova I; Testori A; Conry R; Guillot B; Kruit WHJ; Demidov L; Thompson JA; Bondarenko I; Jaroszek J; Puig S; Cinat G; Hauschild A; Goeman JJ; van Houwelingen HC; Ulloa-Montoya F; Callegaro A; Dizier B; Spiessens B; Debois M; Brichard VG; Louahed J; Therasse P; Debruyne C; Kirkwood JM
    Lancet Oncol; 2018 Jul; 19(7):916-929. PubMed ID: 29908991
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pembrolizumab for Unresectable or Metastatic Melanoma in Patients Older than 85 Years of Age.
    Chanal J; Kramkimel N; Ratour C; Aractingi S; Guégan S; Avril MF
    Dermatology; 2019; 235(3):219-224. PubMed ID: 30721908
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma.
    Hamid O; Puzanov I; Dummer R; Schachter J; Daud A; Schadendorf D; Blank C; Cranmer LD; Robert C; Pavlick AC; Gonzalez R; Hodi FS; Ascierto PA; Salama AKS; Margolin KA; Gangadhar TC; Wei Z; Ebbinghaus S; Ibrahim N; Ribas A
    Eur J Cancer; 2017 Nov; 86():37-45. PubMed ID: 28961465
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Hepatotoxicity After Immune Checkpoint Inhibitor Therapy in Melanoma: Natural Progression and Management.
    Huffman BM; Kottschade LA; Kamath PS; Markovic SN
    Am J Clin Oncol; 2018 Aug; 41(8):760-765. PubMed ID: 28749795
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Tumoral Melanosis in the Setting of Targeted Immunotherapy for Metastatic Melanoma-A Single Institutional Experience and Literature Review.
    Jurgens A; Guru S; Guo R; Brewer J; Bridges A; Jakub J; Comfere N
    Am J Dermatopathol; 2021 Jan; 43(1):9-14. PubMed ID: 32149829
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Nivolumab and pembrolizumab as immune-modulating monoclonal antibodies targeting the PD-1 receptor to treat melanoma.
    Faghfuri E; Faramarzi MA; Nikfar S; Abdollahi M
    Expert Rev Anticancer Ther; 2015; 15(9):981-93. PubMed ID: 26313415
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pembrolizumab and nivolumab: PD-1 inhibitors for advanced melanoma.
    Ivashko IN; Kolesar JM
    Am J Health Syst Pharm; 2016 Feb; 73(4):193-201. PubMed ID: 26843495
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pretreatment metastatic growth rate determines clinical outcome of advanced melanoma patients treated with anti-PD-1 antibodies: a multicenter cohort study.
    Wagner NB; Lenders MM; Kühl K; Reinhardt L; André F; Dudda M; Ring N; Ebel C; Stäger R; Zellweger C; Lang R; Paar M; Gussek P; Richtig G; Stürmer SH; Kimeswenger S; Oellinger A; Forschner A; Leiter U; Weide B; Gassenmaier M; Schraag A; Klumpp B; Hoetzenecker W; Berking C; Richtig E; Ziemer M; Mangana J; Terheyden P; Loquai C; Nguyen VA; Gebhardt C; Meier F; Diem S; Cozzio A; Flatz L; Röcken M; Garbe C; Eigentler TK
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33986126
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial.
    Long GV; Atkinson V; Cebon JS; Jameson MB; Fitzharris BM; McNeil CM; Hill AG; Ribas A; Atkins MB; Thompson JA; Hwu WJ; Hodi FS; Menzies AM; Guminski AD; Kefford R; Kong BY; Tamjid B; Srivastava A; Lomax AJ; Islam M; Shu X; Ebbinghaus S; Ibrahim N; Carlino MS
    Lancet Oncol; 2017 Sep; 18(9):1202-1210. PubMed ID: 28729151
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study.
    Long GV; Atkinson V; Lo S; Sandhu S; Guminski AD; Brown MP; Wilmott JS; Edwards J; Gonzalez M; Scolyer RA; Menzies AM; McArthur GA
    Lancet Oncol; 2018 May; 19(5):672-681. PubMed ID: 29602646
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Acceptability and effectiveness of immunotherapy in patients with melanoma].
    Valnet-Rabier MB; Marcucci C; Limat S; Davani S; Aubin F; Nerich V
    Therapie; 2019 Jun; 74(3):355-367. PubMed ID: 30193804
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Closed system RT-qPCR as a potential companion diagnostic test for immunotherapy outcome in metastatic melanoma.
    Gupta S; McCann L; Chan YGY; Lai EW; Wei W; Wong PF; Smithy JW; Weidler J; Rhees B; Bates M; Kluger HM; Rimm DL
    J Immunother Cancer; 2019 Sep; 7(1):254. PubMed ID: 31533832
    [TBL] [Abstract][Full Text] [Related]  

  • 59. MEK inhibition may increase survival of NRAS-mutated melanoma patients treated with checkpoint blockade: Results of a retrospective multicentre analysis of 364 patients.
    Kirchberger MC; Ugurel S; Mangana J; Heppt MV; Eigentler TK; Berking C; Schadendorf D; Schuler G; Dummer R; Heinzerling L
    Eur J Cancer; 2018 Jul; 98():10-16. PubMed ID: 29843107
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pembrolizumab use for the treatment of advanced melanoma.
    Specenier P
    Expert Opin Biol Ther; 2017 Jun; 17(6):765-780. PubMed ID: 28323504
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.